BENGALURU: India's Hetero Labs said on Friday it sought emergency use nod from the local regulator for Merck's Covid-19 drug molnupiravir, after interim data from a late-stage trial showed it helped reduce hospitalisations and speed up recovery in mild cases.
Molnupiravir is an antiviral drug being developed by Merck & Co (MRK.N) and Ridgeback Biotherapeutics for the treatment of non-hospitalised Covid-19 patients, reports AFP.
The partnerships gave these companies licence to make and supply molnupiravir to India and more than 100 low- and middle-income countries after approvals or emergency authorisations by local regulatory agencies, Merck said in late April.
Hetero said the late-stage trial of molnupiravir, conducted at Covid-19 dedicated hospital sites across India, looked at the drug's efficacy and safety in patients with mild Covid-19.
The data showed the antiviral drug resulted in statistically significant fewer hospital admissions, faster recovery time and early negative SARS-CoV-2 RT PCR results.
Coronavirus cases in India have declined from a devastating peak in April and May. However, health experts have said the country should brace for a third wave by October.
Molnupiravir is currently being tested in a global late-stage study by Merck and partner Ridgeback, with the trial data expected in the fall of 2021.